Prevenar 13
pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor, pharmacist or nurse.
This vaccine has been prescribed for you or your child only. Do not pass it on to others.
If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
What Prevenar 13 is and what it is used for
What you need to know before you or your child receives Prevenar 13
How Prevenar 13 is given
Possible side effects
How to store Prevenar 13
Contents of the pack and other information
Prevenar 13 is a pneumococcal vaccine given to:
caused by 13 types of the bacteria Streptococcus pneumoniae.
Prevenar 13, provides protection against 13 types of Streptococcus pneumoniae bacteria, and replaces Prevenar, which provided protection against 7 types.
The vaccine works by helping the body to make its own antibodies, which protect you or your child against these diseases.
if you or your child is allergic (hypersensitive) to the active substances or to any of the other ingredients in this medicine (listed in section 6) or to any other vaccine that contains diphtheria toxoid.
if you or your child has a severe infection with a high temperature (over 38°C). If this applies to you or your child, then the vaccination will be postponed until you or your child is feeling better. A minor infection, such as a cold, should not be a problem. However, talk to your doctor, pharmacist, or nurse first.
Talk to your doctor, pharmacist, or nurse before the vaccination if you or your child:
has any present or past medical problems after any dose of Prevenar or Prevenar 13 such as an allergic reaction or problems with breathing.
has any bleeding problems or bruises easily.
has a weakened immune system (such as due to HIV infection), you/she/he may not get the full benefit from Prevenar 13.
has experienced seizures as medicines to lower fever may need to be taken before Prevenar 13 is given. If your child should become unresponsive or experience seizures (fits) after the vaccination, please contact your doctor immediately. See also section 4.
Talk to your doctor, pharmacist, or nurse before the vaccination if your child was born very prematurely (at or before 28 weeks of gestation), as longer gaps than normal between breaths may occur for 2-3 days after vaccination. See also section 4.
As with any vaccine, Prevenar 13 will not protect all persons who are vaccinated.
Prevenar 13 will only protect against ear infections in children caused by the types of Streptococcus pneumoniae for which the vaccine has been developed. It will not protect against other infectious agents that can cause ear infections.
Your doctor may ask you to give your child paracetamol or other medicines that lower fever before Prevenar 13 is given. This will help to lower some of the side effects of Prevenar 13.
Tell your doctor, pharmacist or nurse if you or your child is taking, has recently taken or might take any other medicines, or has recently received any other vaccine.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before receiving this medicine.
Prevenar 13 has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4 “Possible side effects” may temporarily affect the ability to drive or use machines.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.
The doctor or nurse will inject the recommended dose (0.5 ml) of the vaccine into your arm or your child's arm or leg muscle.
Infants aged 6 weeks to 6 months of age
Typically, your child should receive an initial course of three injections of the vaccine followed by a booster dose.
The first injection may be given from the age of six weeks.
Each injection will be given at least one month apart.
A fourth injection (booster) will be given between 11 and 15 months of age.
You will be told when your child should come back for the next injection.
According to official recommendations in your country, an alternative schedule may be used by your healthcare provider. Please speak to your doctor, pharmacist, or nurse for more information.
Premature infants
Your child will receive an initial course of three injections. The first injection may be given as early as six weeks of age with at least one month between doses. Between 11 and 15 months of age, your child will receive a fourth injection (booster).
Unvaccinated infants, children, and adolescents over 7 months of age
Infants aged 7 to 11 months should receive two injections. Each injection will be given at least one month apart. A third injection will be given in the second year of life.
Children aged 12 to 23 months should receive two injections. Each injection will be given at least two months apart.
Children aged 2 to 17 years should receive one injection. Infants, children, and adolescents previously vaccinated with Prevenar
Infants and children who have previously received Prevenar may receive Prevenar 13 to complete the course of injections.
For children 1 to 5 years of age previously vaccinated with Prevenar, your doctor or nurse will recommend how many injections of Prevenar 13 are required.
Children and adolescents 6 to 17 years of age should receive one injection.
It is important to follow the instructions from the doctor, pharmacist, or nurse so that your child completes the course of injections.
If you forget to go back at the scheduled time, ask the doctor, pharmacist, or nurse for advice. Adults
Adults should receive one injection.
Tell your doctor, pharmacist or nurse if you have been given a pneumococcal vaccine before.
If you have any further questions on the use of Prevenar 13, ask your doctor, pharmacist, or nurse. Special Populations
Individuals considered to be at a higher risk of pneumococcal infection (such as those with sickle cell disease or HIV infection), including those previously vaccinated with the 23-valent pneumococcal polysaccharide vaccine, may receive at least one dose of Prevenar 13.
Individuals with a blood-forming stem cell transplant may receive three injections, with the first given at 3 to 6 months after the transplant and with an interval of at least 1 month between doses. A fourth injection (booster) is recommended 6 months after the third injection.
Like all vaccines, Prevenar 13 can cause side effects, although not everybody gets them.
Decreased appetite
Fever; irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness; restless sleep
Redness, hardness, swelling at the vaccination-site of 2.5 cm -7.0 cm (after the booster dose and in older children [aged 2 to 5 years])
Vomiting; diarrhoea
Fever of more than 39°C; tenderness at the vaccination-site interfering with movement, redness, hardness, swelling at the vaccination-site of 2.5 cm -7.0 cm (after the initial course of injections)
Rash
Seizures (or fits), including those caused by a high temperature
Hives (urticaria or urticaria-like rash)
Redness, swelling, or hardness at the vaccination-site of more than 7 cm; crying
Collapse or shock-like state (hypotonic-hyporesponsive episode)
Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing
Decreased appetite
Irritability; pain, tenderness, redness, swelling or hardness at the vaccination-site; drowsiness; restless sleep; tenderness at the vaccination-site interfering with movement
Headaches
Vomiting; diarrhoea
Rash; hives (urticaria or urticaria-like rash)
Fever
Children and adolescents with either HIV infection, sickle cell disease or a blood-forming stem cell transplant had similar side effects however the frequencies of headaches, vomiting, diarrhoea, fever, fatigue, joint and muscle pain were very common.
In babies born very prematurely (at or before 28 weeks of gestation), longer gaps than normal between breaths may occur for 2-3 days after vaccination.
Decreased appetite; headaches; diarrhoea; vomiting (for those 18 to 49 years of age)
Chills; tiredness; rash; pain, redness, swelling hardness or tenderness at the vaccination-site, interfering with arm movement (severe pain or tenderness at vaccination-site for those 18-39 years of age and severe limitation of arm movements for those 18 to 39 years of age)
Worsening or new pain in your joints, worsening or new pain in your muscles
Fever (for those 18 to 29 years of age)
Vomiting (for those 50 years and older); fever (for those 30 years and older)
Nausea
Allergic (hypersensitivity) reaction, including swelling of the face and/or lips, difficulty in breathing
Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination-site, such as under the arm
Adults with HIV infection had similar side effects however the frequencies were very common for fever, vomiting and common for nausea.
Adults with a blood-forming stem cell transplant had similar side effects however the frequencies were very common for fever and vomiting.
Severe allergic reaction including shock (cardiovascular collapse); angioedema (swelling of lips, face or throat)
Hives (urticaria), redness and irritation (dermatitis) and itching (pruritus) at the vaccination-site; flushing
Enlarged lymph nodes or glands (lymphadenopathy) near the vaccination-site, such as under the arm or in the groin
A rash causing itchy red blotches (erythema multiforme)
If you or your child get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenational reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.
Store in a refrigerator (2C – 8C). Do not freeze.
Prevenar 13 is stable at temperatures up to 25°C for four days. At the end of this period Prevenar 13 should be used or discarded. These data are intended to guide health care professionals in case of temporary temperature excursions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are polysaccharide CRM197 conjugates consisting of:
2.2 µg of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F
4.4 µg of polysaccharide for serotype 6B
1 dose (0.5 ml) contains approximately 32 µg CRM197 carrier protein, adsorbed on aluminium phosphate (0.125 mg aluminium).
The other ingredients are sodium chloride, succinic acid, polysorbate 80 and water for injections.
The vaccine is a white suspension for injection, provided in a single-dose, pre-filled syringe (0.5 ml). Pack sizes of 1, 10 and 50, with or without needle. Not all pack sizes may be marketed.
Marketing Authorisation Holder: Pfizer Europe MA EEIG Boulevard de la Plaine 17
1050 Bruxelles
Belgium
Manufacturer responsible for batch release: Pfizer Manufacturing Belgium N.V. Rijksweg 12
B-2870 Puurs
Belgium
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Tél/Tel: + 32 (0)2 554 62 11
Pfizer Luxembourg SARL filialas Lietuvoje Tel. + 370 52 51 4000
Пфайзер Люксембург САРЛ, Клон България
Teл: +359 2 970 4333
Pfizer Kft
Tel: +36 1 488 3700
Pfizer, spol. s r.o.
Tel: +420 283 004 111
Vivian Corporation Ltd. Tel: + 35621 344610
Pfizer ApS
Tlf: + 45 44 201 100
Pfizer BV
Tel: +31 (0)10 406 43 01
Pfizer Pharma GmbH
Tel: + 49 (0)30 550055-51000
Pfizer AS
Tlf: +47 67 52 61 00
Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500
Pfizer Corporation Austria Ges.m.b.H Tel: + 43 (0)1 521 15-0
Pfizer Ελλάς A.E.
Τηλ.: +30 210 6785 800
Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00
Pfizer, S.L. Télf:+34914909900
Laboratórios Pfizer, Lda. Tel: +351 21 423 5500
Pfizer
Tél +33 1 58 07 34 40
Pfizer Romania S.R.L Tel: +40 (0) 21 207 28 00
Pfizer Croatia d.o.o. Tel: + 385 1 3908 777
Pfizer Luxembourg SARL
Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana
Tel.: + 386 (0) 1 52 11 400
Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free)
+44 (0)1304 616161
Slovenská republika Pfizer Luxembourg SARL, organizačná zložka
Tel: + 421 2 3355 5500
Icepharma hf
Simi: + 354 540 8000
Pfizer Oy
Puh/Tel: +358 (0)9 430 040
Pfizer S.r.l.
Tel: +39 06 33 18 21
Pfizer AB
Tel: +46 (0)8 550 520 00
Pfizer Ελλάς Α.Ε. (Cyprus Branch) Tηλ: +357 22 817690
Pfizer Limited
Tel: +44 (0) 1304 616161
Pfizer Luxembourg SARL filiāle Latvijā Tel.: + 371 670 35 775
Detailed information on this product is available on the European Medicines Agency website:
----------------------------------------------------------------------------------------------------------------------------
During storage, a white deposit and clear supernatant may be observed. This does not constitute a sign of deterioration.
Inspect visually for any foreign particulate matter and/or abnormal physical appearance; do not use if either are found.
Prior to expelling air from the syringe, shake well to obtain a homogeneous white suspension. Administer the entire dose.
Prevenar 13 is for intramuscular use only. Do not administer intravascularly. Prevenar 13 must not be mixed with any other vaccines in the same syringe.
Prevenar 13 can be given at the same time as other childhood vaccines; in this case, different vaccination sites should be used.
Prevenar 13 may be given to adults aged 50 years and older at the same time as the trivalent or quadrivalent inactivated influenza vaccine.
Any unused product or waste material should be disposed of in accordance with local requirements.